{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:11:59Z","timestamp":1791216719590,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,12,15]],"date-time":"2008-12-15T00:00:00Z","timestamp":1229299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,12,15]],"date-time":"2008-12-15T00:00:00Z","timestamp":1229299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2009,2,19]]},"DOI":"10.1038\/onc.2008.454","type":"journal-article","created":{"date-parts":[[2008,12,16]],"date-time":"2008-12-16T03:59:22Z","timestamp":1229399962000},"page":"1005-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Transforming growth factor-\u03b21 is the predominant isoform required for breast cancer cell outgrowth in bone"],"prefix":"10.1038","volume":"28","author":[{"given":"A A","family":"Mourskaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Banville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Zwaagstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M D","family":"O'Connor-McCourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P M","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,12,15]]},"reference":[{"key":"BFonc2008454_CR1","doi-asserted-by":"publisher","first-page":"6714","DOI":"10.1158\/0008-5472.CAN-05-3565","volume":"66","author":"A Bandyopadhyay","year":"2006","unstructured":"Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM et al. (2006). Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 66: 6714\u20136721.","journal-title":"Cancer Res"},{"key":"BFonc2008454_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13547500701676019","volume":"13","author":"J Baselga","year":"2008","unstructured":"Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A et al. (2008). TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers 13: 217\u2013236.","journal-title":"Biomarkers"},{"key":"BFonc2008454_CR3","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/sj.mt.6300383","volume":"16","author":"S Broussau","year":"2008","unstructured":"Broussau S, Jabbour N, Lachapelle G, Durocher Y, Tom R, Transfiguracion J et al. (2008). Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther 16: 500\u2013507.","journal-title":"Mol Ther"},{"key":"BFonc2008454_CR4","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE . (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s\u20136249s.","journal-title":"Clin Cancer Res"},{"key":"BFonc2008454_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jmb.2005.10.022","volume":"355","author":"G De Crescenzo","year":"2006","unstructured":"De Crescenzo G, Hinck CS, Shu Z, Zuniga J, Yang J, Tang Y et al. (2006). Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor. J Mol Biol 355: 47\u201362.","journal-title":"J Mol Biol"},{"key":"BFonc2008454_CR6","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1158\/0008-5472.CAN-05-3560","volume":"66","author":"M Deckers","year":"2006","unstructured":"Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G et al. (2006). The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66: 2202\u20132209.","journal-title":"Cancer Res"},{"key":"BFonc2008454_CR7","doi-asserted-by":"publisher","first-page":"22765","DOI":"10.1074\/jbc.M401350200","volume":"279","author":"E del Re","year":"2004","unstructured":"del Re E, Babitt JL, Pirani A, Schneyer AL, Lin HY . (2004). In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2. J Biol Chem 279: 22765\u201322772.","journal-title":"J Biol Chem"},{"key":"BFonc2008454_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1349-7006.2006.00357.x","volume":"98","author":"S Ehata","year":"2007","unstructured":"Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K et al. (2007). Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98: 127\u2013133.","journal-title":"Cancer Sci"},{"key":"BFonc2008454_CR9","first-page":"3379","volume":"59","author":"SJ Engle","year":"1999","unstructured":"Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T . (1999). Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59: 3379\u20133386.","journal-title":"Cancer Res"},{"key":"BFonc2008454_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S8756-3282(98)00078-7","volume":"23","author":"AG Geiser","year":"1998","unstructured":"Geiser AG, Zeng QQ, Sato M, Helvering LM, Hirano T, Turner CH . (1998). Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene. Bone 23: 87\u201393.","journal-title":"Bone"},{"key":"BFonc2008454_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.molcel.2007.11.039","volume":"29","author":"J Groppe","year":"2008","unstructured":"Groppe J, Hinck CS, Samavarchi-Tehrani P, Zubieta C, Schuermann JP, Taylor AB et al. (2008). Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 29: 157\u2013168.","journal-title":"Mol Cell"},{"key":"BFonc2008454_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1055\/s-2001-15109","volume":"109","author":"S Hering","year":"2001","unstructured":"Hering S, Isken E, Knabbe C, Janott J, Jost C, Pommer A et al. (2001a). TGFbeta1 and TGFbeta2 mRNA and protein expression in human bone samples. Exp Clin Endocrinol Diabetes 109: 217\u2013226.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"BFonc2008454_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/s-2001-14830","volume":"109","author":"S Hering","year":"2001","unstructured":"Hering S, Isken F, Janott J, Jost C, Pommer A, Muhr G et al. (2001b). Analysis of TGFbeta3 gene expression and protein levels in human bone and serum. Exp Clin Endocrinol Diabetes 109: 107\u2013115.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"BFonc2008454_CR14","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/cncr.21778","volume":"106","author":"KR Hess","year":"2006","unstructured":"Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R et al. (2006). Metastatic patterns in adenocarcinoma. Cancer 106: 1624\u20131633.","journal-title":"Cancer"},{"key":"BFonc2008454_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1210\/er.2004-0001","volume":"26","author":"K Janssens","year":"2005","unstructured":"Janssens K, ten Dijke P, Janssens S, Van Hul W . (2005). Transforming growth factor-beta1 to the bone. Endocr Rev 26: 743\u2013774.","journal-title":"Endocr Rev"},{"key":"BFonc2008454_CR16","doi-asserted-by":"publisher","first-page":"24571","DOI":"10.1074\/jbc.M202561200","volume":"277","author":"SM Kakonen","year":"2002","unstructured":"Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA et al. (2002). Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277: 24571\u201324578.","journal-title":"J Biol Chem"},{"key":"BFonc2008454_CR17","doi-asserted-by":"publisher","first-page":"13909","DOI":"10.1073\/pnas.0506517102","volume":"102","author":"Y Kang","year":"2005","unstructured":"Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR et al. (2005). Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102: 13909\u201313914.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2008454_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","volume":"3","author":"Y Kang","year":"2003","unstructured":"Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537\u2013549.","journal-title":"Cancer Cell"},{"key":"BFonc2008454_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1046\/j.1432-1327.1998.2540505.x","volume":"254","author":"S Komesli","year":"1998","unstructured":"Komesli S, Vivien D, Dutartre P . (1998). Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist. Eur J Biochem 254: 505\u2013513.","journal-title":"Eur J Biochem"},{"key":"BFonc2008454_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","volume":"10","author":"W Kozlow","year":"2005","unstructured":"Kozlow W, Guise TA . (2005). Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10: 169\u2013180.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"BFonc2008454_CR21","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1073\/pnas.90.2.770","volume":"90","author":"AB Kulkarni","year":"1993","unstructured":"Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC et al. (1993). Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90: 770\u2013774.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2008454_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10555-006-9033-z","volume":"25","author":"J Liao","year":"2006","unstructured":"Liao J, McCauley LK . (2006). Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 25: 559\u2013571.","journal-title":"Cancer Metastasis Rev"},{"key":"BFonc2008454_CR23","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/0092-8674(93)90368-Z","volume":"73","author":"F Lopez-Casillas","year":"1993","unstructured":"Lopez-Casillas F, Wrana JL, Massague J . (1993). Betaglycan presents ligand to the TGF beta signaling receptor. Cell 73: 1435\u20131444.","journal-title":"Cell"},{"key":"BFonc2008454_CR24","doi-asserted-by":"publisher","first-page":"63S","DOI":"10.1016\/8756-3282(95)00180-L","volume":"17","author":"SC Manolagas","year":"1995","unstructured":"Manolagas SC . (1995). Role of cytokines in bone resorption. Bone 17: 63S\u201367S.","journal-title":"Bone"},{"key":"BFonc2008454_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1023\/A:1022995403081","volume":"20","author":"AM Mastro","year":"2003","unstructured":"Mastro AM, Gay CV, Welch DR . (2003). The skeleton as a unique environment for breast cancer cells. Clin Exp Metastasis 20: 275\u2013284.","journal-title":"Clin Exp Metastasis"},{"key":"BFonc2008454_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1172\/JCI22320","volume":"115","author":"AJ Minn","year":"2005","unstructured":"Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M et al. (2005). Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115: 44\u201355.","journal-title":"J Clin Invest"},{"key":"BFonc2008454_CR27","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2174\/187152007781668689","volume":"7","author":"AA Mourskaia","year":"2007","unstructured":"Mourskaia AA, Northey JJ, Siegel PM . (2007). Targeting aberrant TGF-beta signaling in pre-clinical models of cancer. Anticancer Agents Med Chem 7: 504\u2013514.","journal-title":"Anticancer Agents Med Chem"},{"key":"BFonc2008454_CR28","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1242\/jcs.02554","volume":"118","author":"A Moustakas","year":"2005","unstructured":"Moustakas A, Heldin CH . (2005). Non-Smad TGF-beta signals. J Cell Sci 118: 3573\u20133584.","journal-title":"J Cell Sci"},{"key":"BFonc2008454_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR . (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584\u2013593.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2008454_CR30","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1128\/MCB.01734-07","volume":"28","author":"JJ Northey","year":"2008","unstructured":"Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ et al. (2008). Signaling through ShcA is required for TGF-{beta} and Neu\/ErbB-2 induced breast cancer cell motility and invasion. Mol Cell Biol 28: 3162\u20133176.","journal-title":"Mol Cell Biol"},{"key":"BFonc2008454_CR31","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW . (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.","journal-title":"Nucleic Acids Res"},{"key":"BFonc2008454_CR32","first-page":"931","volume":"93","author":"AA Rose","year":"2006","unstructured":"Rose AA, Siegel PM . (2006). Breast cancer-derived factors facilitate osteolytic bone metastasis. Bull Cancer 93: 931\u2013943.","journal-title":"Bull Cancer"},{"key":"BFonc2008454_CR33","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/nrm2297","volume":"8","author":"B Schmierer","year":"2007","unstructured":"Schmierer B, Hill CS . (2007). TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 8: 970\u2013982.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFonc2008454_CR34","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/359693a0","volume":"359","author":"MM Shull","year":"1992","unstructured":"Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M et al. (1992). Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693\u2013699.","journal-title":"Nature"},{"key":"BFonc2008454_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0304-3835(01)00524-9","volume":"169","author":"C Sotiriou","year":"2001","unstructured":"Sotiriou C, Lacroix M, Lespagnard L, Larsimont D, Paesmans M, Body JJ . (2001). Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett 169: 87\u201395.","journal-title":"Cancer Lett"},{"key":"BFonc2008454_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/nm0798-802","volume":"4","author":"B Tang","year":"1998","unstructured":"Tang B, Bottinger EP, Jakowlew SB, Bagnall KM, Mariano J, Anver MR et al. (1998). Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 4: 802\u2013807.","journal-title":"Nat Med"},{"key":"BFonc2008454_CR37","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/0092-8674(91)90074-9","volume":"67","author":"XF Wang","year":"1991","unstructured":"Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA . (1991). Expression cloning and characterization of the TGF-beta type III receptor. Cell 67: 797\u2013805.","journal-title":"Cell"},{"key":"BFonc2008454_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/370341a0","volume":"370","author":"JL Wrana","year":"1994","unstructured":"Wrana JL, Attisano L, Wieser R, Ventura F, Massague J . (1994). Mechanism of activation of the TGF-beta receptor. Nature 370: 341\u2013347.","journal-title":"Nature"},{"key":"BFonc2008454_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1172\/JCI3523","volume":"103","author":"JJ Yin","year":"1999","unstructured":"Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R et al. (1999). TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103: 197\u2013206.","journal-title":"J Clin Invest"},{"key":"BFonc2008454_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bbrc.2004.11.070","volume":"328","author":"T Yoneda","year":"2005","unstructured":"Yoneda T, Hiraga T . (2005). Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328: 679\u2013687.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2008454_CR41","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1359\/jbmr.2001.16.8.1486","volume":"16","author":"T Yoneda","year":"2001","unstructured":"Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R . (2001). A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16: 1486\u20131495.","journal-title":"J Bone Miner Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2008454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2008454","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2008454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:18:14Z","timestamp":1647879494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2008454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,15]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,2,19]]}},"alternative-id":["BFonc2008454"],"URL":"https:\/\/doi.org\/10.1038\/onc.2008.454","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,15]]},"assertion":[{"value":"13 August 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}